In accordance to a typical exposure scenario approx. 3 g of the formulation were applied to hands, arms, legs, feet, face and neck of each volunteer (approx. 50% of body surface). At least 26 piston hubs were applied from the pump spray bottle and residual content of

IR3535® in the selleck products bottle was determined thereafter by weighing. Subjects were permitted to take showers 12 h after application of the formulation. Urine samples from the subjects were collected in predetermined intervals (one hour before application, and then 4, 8, 12, 16, 24, 36 and 48 h after application). After determination of the total urine volume, two aliquots of 50 ml were stored at −20 °C. Blood samples (10 mL) were also taken at predefined time points (24 h before application, directly after application of IR3535®, and 0.5, 1,

1.5, 2, 4, 6, 8 and 24 h after application of IR3535®) by the supervising physician with heparinized syringes. Blood samples were immediately centrifuged for 15 min at 1 560 x g to separate erythrocytes and plasma. Plasma samples were then rapidly frozen and stored at −70 °C until further sample preparation and analysis. IR3535®1 and IR3535®-free acid 2 in urine and plasma http://www.selleckchem.com/products/ldk378.html were determined by LC–MS/MS using electrospray ionization. Processed plasma and urine samples were separated on a ReproSil Pur ODS3 HPLC column (2 mm × 150 mm; 5 μm; Maisch, Ammerbuch, Germany) using an Agilent 1100 autosampler and an Agilent 1100 HPLC-pump (Agilent, Waldbronn, Germany). Separation was performed by gradient elution with water containing 0.1% formic acid (solvent A)

and methanol (solvent B) using the following conditions: 90% A, 10% B, isocratic for 2 min, linear increase to 100% B within 10 min, followed by 100% B for 5 min, at a flow-rate of 200 μL/min. The HPLC-system was directly coupled to a triple stage quadrupole mass spectrometer (API 2000 Q-Trap, Applied Biosystems, Darmstadt, Germany). Analytes were detected in the positive-ion mode at a vaporizer temperature of 400 °C and a TurboIon® Spray voltage of +4.0 kV. Spectral data were recorded with nitrogen as collision gas (CAD = 4) in the multiple reaction monitoring (MRM) mode. Mass transitions Baricitinib monitored during the separation are listed in Table 3. The following mass transitions were used for quantification: m/z 180–110 for the internal standard phenacetin, m/z 216–170 for IR3535®1, and m/z 188–86 for IR3535®-free acid 2. Quantification of IR3535®1 and IR3535®-free acid 2 in human plasma was performed in 200 μL aliquots of the plasma samples after thawing at 4 °C for 2 h and fortification with 5 μL of the internal standard phenacetin (1 mg/L in water) (Kress, 2009). Subsequently, 200 μL of methanol were added to each sample. Samples were then vortexed and centrifuged for 20 min at 20.000 × g at 4 °C.